ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Evotec will expand its small-molecule compound management agreement with NIH under a new contract. Since 2004, the company’s Compound Focus subsidiary in South San Francisco has acquired, stored, and distributed compounds for NIH-supported high-throughput screening centers. The new contract extends the agreement for up to 10 years at a value of up to $75 million. In addition, the compounds will now be made available to select outside collaborators. Evotec says it plans to expand its compound management capabilities to the U.S. East Coast and Europe.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X